Invesco DB Agriculture Fund vs Zimmer Biomet Holdings Inc — how do they compare? Invesco DB Agriculture Fund trades at $27.6, while Zimmer Biomet Holdings Inc trades at $89.45 (market cap $17.61B). The key difference: Zimmer Biomet Holdings Inc pays a 1.05% dividend while Invesco DB Agriculture Fund pays none, and Invesco DB Agriculture Fund is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DBA | ZBH | |
|---|---|---|
52-Week High | $28.73 | $107.71 |
52-Week Low | $25.44 | $79.58 |
Market Cap | — | $17.61B |
Sector | — | Health |
Enterprise Value | — | $24.66B |
Dividend Yield | — | 1.05% |
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund) trades at $27.72, down 0.18% with a bullish technical signal supported by moving averages. The ETF tracks agricultural commodities including corn, soybeans, and livestock. Recent news highlights supply disruptions in Brazil's coffee harvest and China's $17 billion U.S. crop purchase commitment through 2028, potentially benefiting agricultural ETFs.
The fund offers exposure to rising commodity prices driven by supply constraints and geopolitical factors, but faces volatility from weather patterns and global demand shifts. Key risks include commodity price fluctuations and concentrated agricultural exposure. Analyst sentiment is mixed with technical indicators showing strength but overbought conditions on shorter-term RSI.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →